DDInter94 DDInter1628
Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta. Anakinra is indicated for the management of rheumatoid arthritis (RA) in patients 18 years of age or older who have failed one or more disease-modifying antirheumatic drugs (DMARDs), as well as the treatment of neonatal-onset multisystem inflammatory disease (NOMID) and deficiency of interleukin-1 receptor antagonist (DIRA). Since IL-1 has an important role in inflammation and immunological responses, anakinra is also used for the off-label treatment of inflammatory diseases. Anakinra is produced using the _
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mycophenolate mofetil
Mycophenolate mofetil {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Altretamine
Altretamine {u} (Compound) causes {v} (Side Effect) Thrombocytopenia
Thrombocytopenia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mycophenolate mofetil
Mycophenolate mofetil {u} (Compound) downregulates {v} (Gene) PLK1
PLK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mycophenolate mofetil
Mycophenolate mofetil {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Prednisone
Prednisone {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mycophenolate mofetil
Mycophenolate mofetil {u} (Compound) downregulates {v} (Gene) TCERG1
TCERG1 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dactinomycin
Dactinomycin {u} (Compound) upregulates {v} (Gene) DNM1
DNM1 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Prednisone
Prednisone {u} (Compound) downregulates {v} (Gene) ZDHHC6
ZDHHC6 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dactinomycin
Dactinomycin {u} (Compound) upregulates {v} (Gene) PHKG2
PHKG2 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexamethasone
Dexamethasone {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil and Mycophenolate mofetil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Altretamine and Altretamine (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Ruxolitinib (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil and Mycophenolate mofetil (Compound) downregulates PLK1 (Gene) and PLK1 (Gene) is bound by Ruxolitinib (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil and Mycophenolate mofetil (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil and Mycophenolate mofetil (Compound) downregulates TCERG1 (Gene) and TCERG1 (Gene) is upregulated by Ruxolitinib (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Dactinomycin and Dactinomycin (Compound) upregulates DNM1 (Gene) and DNM1 (Gene) is downregulated by Ruxolitinib (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone (Compound) downregulates ZDHHC6 (Gene) and ZDHHC6 (Gene) is downregulated by Ruxolitinib (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Dactinomycin and Dactinomycin (Compound) upregulates PHKG2 (Gene) and PHKG2 (Gene) is bound by Ruxolitinib (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)